Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma

NCT02631746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

3

Enrollment

NIH

Sponsor class

Conditions

Acute Adult T-Cell Leukemia/Lymphoma
Adult T-Cell Leukemia/Lymphoma
Chronic Adult T-Cell Leukemia/Lymphoma
HTLV-1 Infection
Lymphomatous Adult T-Cell Leukemia/Lymphoma
Smoldering Adult T-Cell Leukemia/Lymphoma

Interventions

OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab
OTHER: Pharmacogenomic Study

Sponsor

National Cancer Institute (NCI)